Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Breckenridge Pharmaceutical, Inc. announced the signing of a multi-product agreement with Aggrega Pharma, LLC. under which Aggrega will develop, manufacture and supply pharmaceutical products for marketing, sale and distribution by Breckenridge.
read more
Wednesday, January 22, 2020
BridgeBio Pharma announced a collaboration agreement with Catalent to establish dedicated gene therapy development and manufacturing capacity at Catalent’s Paragon Gene Therapy clinical and commercial manufacturing center.
read more
Thursday, October 07, 2021
Brooks Automation announces Brooks Life Sciences Services and Products businesses will be rebranded under the creation of a new identity – Azenta Life Sciences (“Azenta”). Azenta will bring together our existing portfolio of life sciences products ...
read more
Wednesday, March 17, 2021
Bryant Ranch Prepack is voluntarily recalling in total 47 bottles of Spironolactone tablets to the consumer level.
read more
Wednesday, September 14, 2022
Following their recent expansion into formulation, method and lyo development, Berkshire Sterile Manufacturing (BSM) now offers two new services to assist their clients in their R&D efforts as they head towards clinical development and trials.
read more
Wednesday, March 11, 2020
Burke Therapeutics has signed an exclusive marketing and supply agreement with Coeptis for the U.S. market.
read more
Thursday, October 31, 2013
The U.S. regulatory landscape changed dramatically 10 years ago. In 2003, legal roadblocks to the 505(b)(2) approval pathway were resolved, making it a practical alternative route for drug development. That same year, Ken Phelps and Ruth Stevens ...
read more
Monday, February 09, 2015
Camargo Pharmaceutical Services, a leading drug development organization specializing in the 505(b)(2) approval pathway, will reveal its new brand at the Generic Pharmaceutical Association (GPhA) Annual Meeting. The new brand comes as 505(b)(2) is ...
read more
Wednesday, November 27, 2013
Jim Beach, a veteran health care executive with broad
experience in operations, R&D, marketing and sales, has been named chief operating officer for
Camargo Pharmaceutical Services, a leading drug development organization specializing in the
505(b...
read more
Tuesday, October 24, 2017
Cambrex announced the completion of an expansion to its large scale production capacity at its Iowa plant.
read more
Wednesday, January 02, 2019
Cambrex has completed the acquisition of Avista Pharma Solutions, a contract development, manufacturing, and testing organization, from Ampersand Capital Partners.
read more
Cambrex announced that it has completed the construction of a $24 million highly potent API (HPAPI) manufacturing facility at its site in Charles City, IA.
read more
Wednesday, April 13, 2022
Cambrex announced the completion of a $50 million expansion of its large-scale active pharmaceutical ingredient (API) manufacturing capabilities at its Charles City, Iowa facility.
read more
Wednesday, March 27, 2019
Cambrex announced it will double the liquid packaging capacity and weekly output at its Mirabel, Québec site in Canada.
read more
Cambrex Corporation will expand research and development capabilities at its site in Paullo, Milan, Italy.
read more